WHO published first Hep C Guideline

[benjanim]

Post: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/

Guideline PDF: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1

[dontworry_behappy1]

"The guidance was developed by a panel of HCV experts in the field of hepatogy and infections diseases, using an evidence-based review of information that is largely available to healthcare practitioners."   This statement is from the published site below.  

www.hcvguidelines.org

[JimmyMose]

Great post. Didn't see it because I was creating a similar one and posted just minutes after yours. Rightly so MHMod removed it.

A few more excerpt details  Publication date: April 2014
__________________________________________________________
This guidance includes recommendations for all medicines approved as
of December 2013, and will be updated periodically as new compounds become available for use.  

Summary of recommendations
6. Treatment with pegylated interferon and ribavirin: Pegylated interferon in
combination with ribavirin is recommended for the treatment of chronic
HCV infection rather than standard non-pegylated interferon with ribavirin.
(Strong recommendation, moderate quality of evidence)
7. Treatment with telaprevir or boceprevir: Treatment with the direct-acting
antivirals telaprevir or boceprevir, given in combination with pegylated
interferon and ribavirin, is suggested for genotype 1 chronic HCV
infection rather than pegylated interferon and ribavirin alone. (Conditional
recommendation, moderate quality of evidence)
8. Treatment with sofosbuvir: Sofosbuvir, given in combination with ribavirin
with or without pegylated interferon (depending on the HCV genotype), is
recommended in genotypes 1, 2, 3 and 4 HCV infection rather than pegylated interferon and ribavirin alone (or no treatment for persons who cannot tolerate interferon). (Strong recommendation, high quality of evidence)
9. Treatment with simeprevir: Simeprevir, given in combination with pegylated interferon and ribavirin, is recommended for persons with genotype 1b HCV infection and for persons with genotype 1a HCV infection without the Q80K polymorphism rather than pegylated interferon and ribavirin alone. (Strong recommendation, high quality of evidence)
Note: Recommendations 8 and 9 were made without taking resource use into consideration, as pricing information was not available for any country other than the United States at the time this recommendation was formulated.
___________________________________________________________

The WHO guidelines are for the world in general and the drugs that are or may be available to a country. and were from December 2013 discussions.

hcvguidelines.org guidlines are primarly for the USA FDA approved drugs, Off-Label recommendations and the non recommendation of older treatments still approved by the FDA.